{"id":"https://openalex.org/W4361237151","doi":"https://doi.org/10.1158/0008-5472.22414010","title":"Tables S1, S2, S4, S8, S9 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy","display_name":"Tables S1, S2, S4, S8, S9 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361237151","doi":"https://doi.org/10.1158/0008-5472.22414010"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.22414010","doi":"https://doi.org/10.1158/0008-5472.22414010","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22414010","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Tables_S1_S2_S4_S8_S9_from_MAPK_Signaling_and_Inflammation_Link_Melanoma_Phenotype_Switching_to_Induction_of_CD73_during_Immunotherapy/22414010/1/files/39860027.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Tables_S1_S2_S4_S8_S9_from_MAPK_Signaling_and_Inflammation_Link_Melanoma_Phenotype_Switching_to_Induction_of_CD73_during_Immunotherapy/22414010/1/files/39860027.pdf","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Julia Reinhardt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Julia Reinhardt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102705110","display_name":"Jennifer Landsberg","orcid":"https://orcid.org/0000-0003-2362-5831","observed_orcids":["https://orcid.org/0000-0003-2362-5831"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer Landsberg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032273611","display_name":"Jonathan Leo Schmid-Burgk","orcid":"https://orcid.org/0000-0003-0988-2487","observed_orcids":["https://orcid.org/0000-0003-0988-2487"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jonathan L. Schmid-Burgk","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073940249","display_name":"Bartomeu Bibiloni Ramis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bartomeu Bibiloni Ramis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025785991","display_name":"Tobias Bald","orcid":"https://orcid.org/0000-0003-0061-235X","observed_orcids":["https://orcid.org/0000-0003-0061-235X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tobias Bald","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008698954","display_name":"Nicole Glodde","orcid":"https://orcid.org/0000-0002-7012-6034","observed_orcids":["https://orcid.org/0000-0002-7012-6034"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicole Glodde","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043373712","display_name":"Dorys Lopez-Ramos","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dorys Lopez-Ramos","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040207559","display_name":"Arabella Young","orcid":"https://orcid.org/0000-0002-6845-9753","observed_orcids":["https://orcid.org/0000-0002-6845-9753"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Arabella Young","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054642059","display_name":"Shin Foong Ngiow","orcid":"https://orcid.org/0000-0002-5738-2834","observed_orcids":["https://orcid.org/0000-0002-5738-2834"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shin Foong Ngiow","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051141861","display_name":"Daniel Nettersheim","orcid":"https://orcid.org/0000-0002-4483-845X","observed_orcids":["https://orcid.org/0000-0002-4483-845X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Nettersheim","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015796348","display_name":"Hubert Schorle","orcid":"https://orcid.org/0000-0001-8272-0076","observed_orcids":["https://orcid.org/0000-0001-8272-0076"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hubert Schorle","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044221013","display_name":"Thomas Quast","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas Quast","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012137496","display_name":"Waldemar Kolanus","orcid":"https://orcid.org/0000-0003-1325-9444","observed_orcids":["https://orcid.org/0000-0003-1325-9444"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Waldemar Kolanus","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034365278","display_name":"Dirk Schadendorf","orcid":"https://orcid.org/0000-0003-3524-7858","observed_orcids":["https://orcid.org/0000-0003-3524-7858"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dirk Schadendorf","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070576000","display_name":"Georgina Venetia Long","orcid":"https://orcid.org/0000-0001-8894-3545","observed_orcids":["https://orcid.org/0000-0001-8894-3545"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Georgina V. Long","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030018577","display_name":"Jason Madore","orcid":"https://orcid.org/0000-0002-3499-474X","observed_orcids":["https://orcid.org/0000-0002-3499-474X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jason Madore","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083653505","display_name":"Richard A. Scolyer","orcid":"https://orcid.org/0000-0002-8991-0013","observed_orcids":["https://orcid.org/0000-0002-8991-0013"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard A. Scolyer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083745558","display_name":"Antoni Ribas","orcid":"https://orcid.org/0000-0003-3669-8458","observed_orcids":["https://orcid.org/0000-0003-3669-8458"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Antoni Ribas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061575707","display_name":"Mark John Smyth","orcid":"https://orcid.org/0000-0001-7098-7240","observed_orcids":["https://orcid.org/0000-0001-7098-7240"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark J. Smyth","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081677088","display_name":"Paul C. Tumeh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul C. Tumeh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078324938","display_name":"Thomas T\u00fcting","orcid":"https://orcid.org/0000-0001-7146-0934","observed_orcids":["https://orcid.org/0000-0001-7146-0934"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas T\u00fcting","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5010759010","display_name":"Michael H\u00f6lzel","orcid":"https://orcid.org/0000-0003-4048-8824","observed_orcids":["https://orcid.org/0000-0003-4048-8824"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael H\u00f6lzel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8246999979019165,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8246999979019165,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.10329999774694443,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":0.0340999998152256,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9610000252723694},{"id":"https://openalex.org/keywords/cd73","display_name":"CD73","score":0.9649999737739563},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.8539999723434448},{"id":"https://openalex.org/keywords/inflammation","display_name":"inflammation","score":0.9110000133514404},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.6639999747276306},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.8519999980926514},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9869999885559082},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.8669999837875366},{"id":"https://openalex.org/keywords/nt5e","display_name":"NT5E","score":0.8880000114440918},{"id":"https://openalex.org/keywords/transcription-factor-binding","display_name":"transcription factor binding","score":0.7390000224113464}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.8760621547698975},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6841648817062378},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.673513650894165},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6186175346374512},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.5919766426086426},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5302058458328247},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5067008137702942},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5033213496208191},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3483814001083374},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.34201592206954956}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/0008-5472.22414010","doi":"https://doi.org/10.1158/0008-5472.22414010","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22414010","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Tables_S1_S2_S4_S8_S9_from_MAPK_Signaling_and_Inflammation_Link_Melanoma_Phenotype_Switching_to_Induction_of_CD73_during_Immunotherapy/22414010/1/files/39860027.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/0008-5472.22414010","doi":"https://doi.org/10.1158/0008-5472.22414010","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22414010","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Tables_S1_S2_S4_S8_S9_from_MAPK_Signaling_and_Inflammation_Link_Melanoma_Phenotype_Switching_to_Induction_of_CD73_during_Immunotherapy/22414010/1/files/39860027.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8199999928474426,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361237151.pdf","grobid_xml":"https://content.openalex.org/works/W4361237151.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2903811712","https://openalex.org/W4292373623","https://openalex.org/W2981883049","https://openalex.org/W3215044659","https://openalex.org/W2988525911","https://openalex.org/W2915045061","https://openalex.org/W2607780130","https://openalex.org/W2342781363","https://openalex.org/W4221021748","https://openalex.org/W3035446385"],"abstract_inverted_index":{"Supplemental":[0,9,24,39,58],"Table":[1,10,25,40,59],"S1.":[2],"DNA":[3],"oligos":[4],"used":[5],"in":[6,32,47],"this":[7],"study":[8],"S2.":[11],"Characteristics":[12,61],"of":[13,28,43,64,67,71],"patients":[14,49,70],"with":[15,76],"primary":[16],"melanomas":[17,68],"and":[18,62],"cutaneous":[19],"melanoma":[20,48],"metastasis":[21],"(Bonn":[22],"cohorts).":[23],"S4.":[26],"List":[27],"transcription":[29],"factors":[30],"binding":[31],"NT5E":[33],"based":[34],"on":[35],"ENCODE":[36],"ChIP-seq":[37],"data.":[38],"S8.":[41],"Changes":[42],"CD73":[44,65],"IHC":[45],"score":[46],"from":[50,69],"the":[51,72],"UCLA":[52],"cohort":[53,74],"under":[54],"pembrolizumab":[55,79],"treatment":[56],"(anti-PD-1).":[57],"S9.":[60],"changes":[63],"expressions":[66],"Sydney":[73],"treated":[75],"nivolumab":[77],"or":[78],"(anti":[80],"PD-1).":[81]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-10-10T00:00:00"}